XBiotech (XBIT) shares were down over 25% Monday after the company said it is pausing its rheumatology clinical program due to irregularities in the phase II study of its candidate drug Natrunix for rheumatoid arthritis.
The study, which included about 230 participants with moderate to severe rheumatoid arthritis, did not achieve its primary endpoint of an American College of Rheumatology response rate after 12 weeks, the company said.
XBiotech said it found irregularities at the top enrolling clinical sites, including multiple enrollments of the same subjects, which raised concerns about data validity. As a result, the company has paused further planned studies in arthritis and ankylosing spondylitis while it evaluates the findings.
Price: 4.78, Change: -1.60, Percent Change: -25.08
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。